XM n’offre pas ses services aux résidents des États-Unis d’Amérique.

Markets stay bumpy awaiting jobs reality check



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>MORNING BID AMERICAS-Markets stay bumpy awaiting jobs reality check</title></head><body>

A look at the day ahead in U.S. and global markets from Mike Dolan

Seeking some calm, markets remain edgy following the volatility jolt of the past week and traders now seek some re-assurance the real economy has not shifted underneath them.

Volatility spikes like the one seen on Monday rarely disappear instantly and, with the VIX 'fear gauge' .VIX still above historical averages of about 20, some turbulence remains. At less than half Monday's peak, however, some healing is underway.

The jangled nerves were evident on Wednesday as an initial bounce in Wall St stocks faded by the close, with anxiety fed by another red flag on the artificial intelligence theme from Super Micro's poor results and after a messy 10-year Treasury auction.

To be sure, the 10-year note sale US10YT=RR was allocated at 3 basis points above pre-auction levels and demand at 2.32 times the paper on offer was the lowest in almost two years. But that mostly reflected the week's sudden swoon in yields below 4% and the $42 billion sale went off with funding for Treasury almost 15bp cheaper than it would have got a week ago.

Some $25 billion of 30-year bonds are up for grabs later on Thursday and provide the latest test - with the 2-to-30-year Treasury yield curve now positive to the tune of 27bps, having hit its steepest in two years on Monday. The 2-to-10 curve remains slightly inverted.

Attention now turns back to whether the U.S. labor market is weakening at a pace that Friday's payrolls report suggested and the release on Thursday of the weekly jobless claims report takes on elevated significance for markets still largely priced for a Federal Reserve rate cut of up to 50bps next month.

New unemployment claims have been rising and hit their highest since August last year in the most recent week.

Stock futures ESc1, NQcv1 were steady ahead of the open today, however, with the VIX remaining below 30.

European .STOXXE and Asian benchmarks were slightly lower - but with far less movement than earlier in the week. China's mainland index .CSI300 was marginally higher.

It was nervy still in Japan - the epicentre of much of the past week's angst due to unwinding short yen 'carry trades' that seeded wild 10%-plus swings in the Nikkei stock index .N225. But with a loss on Thursday of less than 1%, it appeared almost serene by comparison with Monday and Tuesday.

There were some concerns from the minutes of last week's rate-raising Bank of Japan meeting, which showed board members calling for the need to keep raising interest rates.

But that was recorded before the market turbulence that has since seen BOJ top brass say they would stall on that if it were just to fuel more market disruption.

And Finance Minister Shunichi Suzuki said on Thursday the authorities were closely watching stock market developments, even if not yet planning specific actions yet.

With estimates that most of the outstanding yen carry trades had now been unwound, the dollar/yen exchange rate steadied and retained a perch above 146. The dollar index .DXY more broadly edged lower as two and 10-year Treasury yields subsided once more in early trading on Thursday.

In earnings, there will be a close look at pharma giant Eli Lilly's results.

European rival Novo Nordisk NOVOb.CO on Wednesday reported weaker-than-expected quarterly sales of its popular weight-loss drug Wegovy, stirring worries among investors about stiffening competition from Eli Lilly and sending its shares down 8%.

Novo is spending billions of dollars to lift Wegovy production to meet demand and fend off Lilly, which launched its rival therapy Zepbound in the U.S. last December. While the two companies are now going head-to-head with obesity treatments in a number of markets - the most lucrative one by far is the U.S., where more than 70% of adults are obese or overweight.


Key developments that should provide more direction to U.S. markets later on Thursday:

* US weekly jobless claims, June wholesales sales; Mexico July inflation

* Richmond Federal Reserve President Thomas Barkin speaks

* Central Bank of Mexico policy decision

* US corporate earnings: Eli Lilly, Gilead Sciences, News Corp, Paramount Global, Expedia, Insulet, Solventum, Take-Two Interactive Software, Akamai Technologies, Epam Systems, Viatris, Martin Marietta Materials, Parker-Hannifan, NRG Energy, Vistra

* US Treasury sells $25 billion of 30-year bonds, $95 billion of 4-week bills


Markets assuming deeper Fed rate cuts after soft jobs data, volatility spike https://reut.rs/4df7NDF

US unemployment claims rising https://reut.rs/3SxUjdA

Credit conditions matter https://reut.rs/3WAL262

Mortgage refinancing activity on the rise https://reut.rs/3MgVkUd

Tech valuations cheaper, but are they cheap? https://reut.rs/4cgMZu0


By Mike Dolan; Editing by Toby Chopra
mike.dolan@thomsonreuters.com

</body></html>

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques